- New alliance will crack down on adulterated products touting dietary supplement claims
- Adherence among chronic disease patients can lead to big savings
- New strength of Intelence gets regulatory approval
- Pernix, ParaPro to promote prescription pediculicide if approved
- FDA releases annual 'Generic Drug Roundup'
TITUSVILLE, N.J. — The Food and Drug Administration has approved a revised dosage for a drug combination, which includes a Johnson & Johnson drug, in HIV patients who have received treatment but whose virus has not become immune to the J&J drug.
Tibotec Therapeutics, a J&J subsidiary, announced the FDA’s approval in adults of a once-daily combination of its Prezista (darunavir) and Abbott’s Norvir (ritonavir), which combines 800 mg of Prezista with 100 mg of Norvir. The previously approved dosage was 600 mg of Prezista and 100 mg of Norvir taken twice per day.
“With this once-daily dosing recommendation, boosted Prezista is now a viable option for more treatment-experienced patients,” Tibotec president Glenn Mattes said. “This approval reflects Tibotec’s ongoing commitment to optimizing dosing strategies for HIV patients.”